These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 3053039)

  • 1. Calcium carbonate and magnesium hydroxide in the prevention of renal osteodystrophy or the demise of aluminum toxicity in uremia. Analysis of 5 years experience.
    Morinière P; Fournier A; Westeel PF; Idrissi A; Renaud H; Hocine C; Belbrik S; Marie A; Leflon P; Sebert JL
    Contrib Nephrol; 1988; 64():58-73. PubMed ID: 3053039
    [No Abstract]   [Full Text] [Related]  

  • 2. [Current aspects of the therapy of uremic hyperphosphatemia].
    Schaefer K; von Herrath D; Erley CM
    Dtsch Med Wochenschr; 1987 Oct; 112(44):1707-12. PubMed ID: 3311696
    [No Abstract]   [Full Text] [Related]  

  • 3. Magnesium hydroxide is a useful complementary aluminum-free phosphate binder to moderate doses of oral calcium in uremic patients on chronic hemodialysis.
    Fournier A; Moriniere P
    Clin Nephrol; 1988 Jun; 29(6):319. PubMed ID: 3396236
    [No Abstract]   [Full Text] [Related]  

  • 4. [Role of calcium carbonate in the treatment of renal osteodystrophy].
    Morinière P; Boudailliez B; Westeel PF; Achard JM; Djerad M; Nahle M; Amar M; Fournier A
    Nephrologie; 1991; 12(1):31-41. PubMed ID: 2034319
    [No Abstract]   [Full Text] [Related]  

  • 5. Preventing renal bone disease in moderate renal failure with CaCO3 and 25(OH) vitamin D3.
    Fournier A; Idrissi A; Sebert JL; Gueris J; Garabedian M; Renaud H; Westeel PF
    Kidney Int Suppl; 1988 Mar; 24():S178-9. PubMed ID: 3163044
    [No Abstract]   [Full Text] [Related]  

  • 6. Alternative phosphate binders in dialysis patients: calcium carbonate.
    Slatopolsky E; Weerts C; Stokes T; Windus D; Delmez J
    Semin Nephrol; 1986 Dec; 6(4 Suppl 1):35-41. PubMed ID: 3602677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interaction of parathyroid hormone and aluminum in renal osteodystrophy.
    Slatopolsky E
    Kidney Int; 1987 Mar; 31(3):842-54. PubMed ID: 3573543
    [No Abstract]   [Full Text] [Related]  

  • 8. [Considerations on antacid therapy].
    Holtermüller KH; Bohlen E; Castro M; Weis HJ
    Med Klin; 1977 Jul; 72(30):1229-41. PubMed ID: 329089
    [No Abstract]   [Full Text] [Related]  

  • 9. Reversal of aluminum-related bone disease after substituting calcium carbonate for aluminum hydroxide.
    Hercz G; Andress DL; Nebeker HG; Shinaberger JH; Sherrard DJ; Coburn JW
    Am J Kidney Dis; 1988 Jan; 11(1):70-5. PubMed ID: 3337101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of dental caries.
    Gilders BT
    Br Dent J; 1980 Oct; 149(8):222. PubMed ID: 6932894
    [No Abstract]   [Full Text] [Related]  

  • 11. Magnesium hydroxide as a complementary aluminium-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis: lack of deleterious effect on bone mineralisation.
    Morinière P; Vinatier I; Westeel PF; Cohemsolal M; Belbrik S; Abdulmassih Z; Hocine C; Marie A; Leflon P; Roche D
    Nephrol Dial Transplant; 1988; 3(5):651-6. PubMed ID: 3146723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for renal osteodystrophy: a multivariant analysis.
    Pei Y; Hercz G; Greenwood C; Segre G; Manuel A; Saiphoo C; Fenton S; Sherrard D
    J Bone Miner Res; 1995 Jan; 10(1):149-56. PubMed ID: 7747622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Magnesium hydroxide treatment of hyperphosphatemia in chronic hemodialysis patients with an aluminum overload].
    Roujouleh H; Lavaud S; Toupance O; Melin JP; Chanard J
    Nephrologie; 1987; 8(2):45-50. PubMed ID: 3614505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium carbonate: a suitable alternative to aluminum hydroxide as phosphate binder.
    Malberti F; Surian M; Colussi G; Poggio F; Minoia C; Salvadeo A
    Kidney Int Suppl; 1988 Mar; 24():S184-5. PubMed ID: 3163047
    [No Abstract]   [Full Text] [Related]  

  • 16. [Evidence of the cytoprotective action of antacids. Behavior of the transmural stomach electric potential difference with antacids in healthy subjects and stomach ulcer patients].
    Tympner F
    Fortschr Med; 1985 Sep; 103(33):795-8. PubMed ID: 4054802
    [No Abstract]   [Full Text] [Related]  

  • 17. Role of aluminum in uremic osteodystrophy.
    Luciani L; Rovelli E; Colleoni N; Mocetti P; Ballanti P; Bonucci E; D'Amico G
    Contrib Nephrol; 1990; 77():168-76. PubMed ID: 2188785
    [No Abstract]   [Full Text] [Related]  

  • 18. Calcium carbonate, an aluminum-free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism in uremia.
    Fournier A; Moriniere P; Sebert JL; Dkhissi H; Atik A; Leflon P; Renaud H; Gueris J; Gregoire I; Idrissi A
    Kidney Int Suppl; 1986 Feb; 18():S114-9. PubMed ID: 3457987
    [No Abstract]   [Full Text] [Related]  

  • 19. [High doses of calcium carbonate or the combination of 1 alpha hydroxylated derivatives of vitamin D and aluminum compounds bound to phosphorus in the preventive treatment of renal osteodystrophy].
    Fournier A; Morinière P; Boudailliez B; Marie A; Westeel PF; Renaud M; Belbrik S; Hocine C; Sebert JL
    Presse Med; 1988 Apr; 17(16):777-80. PubMed ID: 2968564
    [No Abstract]   [Full Text] [Related]  

  • 20. Calcium beta-hydroxy-beta-methylbutyrate. 1. Potential role as a phosphate binder in uremia: in vitro study.
    Sousa MF; Abumrad NN; Martins C; Nissen S; Riella MC
    Nephron; 1996; 72(3):391-4. PubMed ID: 8852485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.